Natural Product (NP) hit confirmation and validation foresee fast conversion into qualified lead series. Therefore, the assessment of physicochemical and pharmacological properties has to be conducted at very early stages of drug discovery. Accelerated conversion of hits into leads and then into qualified development candidates support successful lead generation.
Bicoll owns pre-selection technique in early drug development. Moreover, high throughput prediction toolbox enables reducing the attrition rate of potential drug candidates as they progress through development. In this case identification and sort out “troublemaker-compounds” up-front significantly lower screening costs and increase productivity.
The aim is to structurally modify the lead compound. The reason is here to improve both the affinity for the target and specific ADME / Tox properties. Lead Optimization proceeds with the development of mentioned properties.
Certainly, high potency of natural products and their proven capability to influence cell metabolism is promoted by data of selected early ADME properties. In short, this data will help to focus resources on the promising compounds exclusively.
According to new research, hit-to-lead processes will account for the fastest-growing segment of the drug discovery service market in the forecast period 2020 to 2025. Reportlinker, says that overall, the drug discovery service market if set to be worth $21.4 billion by 2025, up from $11.1 billion in 2020. The report highlights that this market will witness a compound annual growth rate (CAGR) of 14 percent.
More information on hit-to-lead you can find here.